Evidence map›Paper›PMID 41042068›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Tumor Intrinsic METTL5 Modulates ATF4 Translation to Prevent T Cell-Induced Ferroptosis in Ovarian Cancer.

Jiakai Hou, Cheng-Wei Ju, Nicholas A Egan, Yanjun Wei, Yunfei Wang, Minghao Dang, Tianyi Zhou, Leilei Shi, Ningbo Zheng, Si Chen and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. METTL5 in physiology and pathology: mechanisms and implications.Frontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Jiakai HouDepartment of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA.
Cheng-Wei JuDepartment of Chemistry, The University of Chicago, Chicago, IL, 60637, USA.
Nicholas A EganDepartment of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA.
Yanjun WeiDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Yunfei WangClinical Science Lab, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA.
Minghao DangDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Tianyi ZhouDepartment of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA.
Leilei ShiDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Ningbo ZhengDepartment of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA.
Si ChenDepartment of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA.
Ashley M GuerreroDepartment of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA.
Xiaofang LiangDepartment of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA.
Wanfu WuDepartment of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA.
Areej AkhtarDepartment of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA.
Chitra DhimanDepartment of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA.
Debanwita Roy BurmanDepartment of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA.
Andro E GergesDepartment of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA.
Mason D FloresDepartment of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA.
Han LiDepartment of Chemistry, The University of Chicago, Chicago, IL, 60637, USA.
Li-Sheng ZhangDepartment of Chemistry, The University of Chicago, Chicago, IL, 60637, USA.
Marleen KokDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, 1066 CX, The Netherlands.
Xiaobo MaoNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21218, USA.
Linghua WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Qin FengDepartment of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA.
Yiwen ChenDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Sanghoon LeeDepartment of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Daniel J McGrailCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, 44195, USA.
Nidhi SahniDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Chuan HeDepartment of Chemistry, The University of Chicago, Chicago, IL, 60637, USA.
Amir A JazaeriDepartment of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Weiyi PengDepartment of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA.ORCID https://orcid.org/0000-0002-7785-6240

Funding

Transcriptome-wide base-resolution sequencing of pseudouridine in human normal and AD brain tissues-CEGS Admin supplement 2020-2021RM1HG008935 · NHGRI · UNIVERSITY OF CHICAGO · PI HE, CHUAN · 2016 to 2025
$24.4M
Computational and experimental approaches for decoding the function and regulation of unconventional RNA translationR35GM156417 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Yiwen Chen · 2025 to 2026
$899k
American Cancer Society 1155993Andrew Sabin Family Foundation FellowshipBlanton-Davis Ovarian Cancer Research ProgramCancer Prevention and Research Institute of Texas RP200520(PWY)Cancer Prevention and Research Institute of Texas RR160021(NS)Early Career Award by Ovarian Cancer Research Alliance 649968Howard Hughes Medical InstituteLudwig Cancer Research FoundationNHGRI NIH HHS RM1 HG008935NHGRI NIH HHS RM1HG008935(CH)NIGMS NIH HHS R35 GM156417NIGMS NIH HHS R35GM156417(YC)
6 · The paper itself

Abstract

Poor clinical responses to immune checkpoint blockade (ICB) observed in ovarian cancer (OC) highlight an unmet need to understand the mechanisms driving immune evasion in this disease. To address this, an integrative analysis is conducted by combining in vitro genome-wide immune screens, in vivo ICB screens, and clinical data mining, and METTL5 is identified as a crucial OC-intrinsic factor that promotes immune resistance. Immunologically "cold" OC tumors and poor responders to ICB exhibit elevated METTL5 expression. Mechanistically, knocking out (KO) METTL5 in OC disrupts ATF4 translation by altering 18S rRNA m

Indexed as

Activating Transcription Factor 4FerroptosisMethyltransferasesOvarian NeoplasmsT-LymphocytesAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMiceActivating Transcription Factor 4ATF4 protein, humanMethyltransferasesATF4CRISPR screenferroptosisimmunotherapyMETTL5ovarian cancer

Identifiers

PMID41042068
PMCPMC12697795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.